Xeris Biopharma Holdings, Inc.
NASDAQ:XERSBiotechnology
+$0.04 today
- Market cap
- $3.10B
- Beta
- 0.90
- P/E (TTM)
- 98.7
- EPS (TTM)
- $0.07
Volume 2.76M
Average 1.66M
XERS Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Xeris Biopharma Holdings, Inc.NASDAQ: XERS
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 211.5% from a year ago
Other current liabilities stood at $100.86M at the end of Q1 FY2026, up 211.5% from a year earlier and up 0.6% from the prior quarter. Over 3 fiscal years it compounded at +54.4% a year.
Context
- Other current liabilities amounted to 25.7% of total assets at the end of Q1 FY2026, up 15.5 pp from a year earlier.
- Other current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +211.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 100.27M USD
- Year-over-year change
- +152.3%
- 4-year CAGR
- +40.6%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 100.27M | +152.3% |
| FY2024 | 2024-12-31 | 39.75M | -22.7% |
| FY2023 | 2023-12-31 | 51.43M | +88.9% |
| FY2022 | 2022-12-31 | 27.23M | +6.3% |
| FY2021 | 2021-12-31 | 25.63M | — |
Other Current Liabilities vs competitors
How XERS compares with its peers on the latest reported figures
- Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +211.5% is the highest of 9, against a peer median of -8.8%.
- Other current liabilities amounts to 25.7% of total assets for XERS, versus a peer median of 6.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | €365.32M EUR | -13.0% | +37.8% | 15.1% | |
| Jun 2026 | $136.98M USD | +46.0% | +0.4% | 15.4% | |
| Mar 2026 | $100.86M USD | +211.5% | +54.4% | 25.7% | |
| Mar 2026 | $64.98M USD | +122.2% | +61.9% | 8.7% | |
SEPNSepterna, Inc. | Sep 2026 | $26.4M USD | -57.2% | +51.2% | 4.3% |
| Mar 2026 | $18.89M USD | -4.6% | — | 19.3% | |
| Mar 2026 | $6.25M USD | +29.9% | +9.3% | 2.3% | |
| Mar 2026 | $640K USD | -58.0% | +11.3% | 1.1% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $0 USD | -100.0% | +56.2% | 0.0% |
| Peer median (excluding XERS) | — | -8.8% | +37.8% | 6.5% | |
Competitors are the stored peer set for XERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 67.27M | 121.97M | 67.45M | 71.62M | 111.04M |
| Short-term Investments | 35.16M | 0 | 5M | 0 | 0 |
| Net Receivables | 17.46M | 30.83M | 39.2M | 40.42M | 51.05M |
| Inventory | 18.12M | 24.74M | 38.84M | 48.18M | 68.67M |
| Other Current Assets | 0 | 9.29M | 5.78M | 7.45M | 9.55M |
| Total Current Assets | 142.6M | 186.82M | 156.26M | 167.66M | 240.31M |
| Property, Plant & Equipment (Net) | 6.63M | 9.51M | 29.18M | 28.21M | 27.06M |
| Goodwill | 22.86M | 22.86M | 22.86M | 22.86M | 22.86M |
| Intangible Assets | 131.45M | 120.61M | 109.76M | 98.92M | 88.08M |
| Long-term Investments | 0 | 0 | 0 | 4.12M | 0 |
| Tax Assets | 0 | 0 | 0 | 6.09M | 0 |
| Other Non-current Assets | 829K | 4.73M | 4.54M | (4.81M) | 5.22M |
| Total Non-current Assets | 161.77M | 157.7M | 166.34M | 155.4M | 143.21M |
| Total Assets | 304.36M | 344.52M | 322.6M | 323.06M | 383.53M |
| Account Payables | 8.92M | 4.61M | 11.57M | 2.29M | 3.08M |
| Short-term Debt | 0 | 0 | 0 | 15.1M | 6.23M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 25.63M | 27.23M | 51.43M | 39.75M | 100.27M |
| Total Current Liabilities | 79.04M | 73.62M | 95.19M | 100.44M | 109.57M |
| Long-term Debt | 88.07M | 187.08M | 190.93M | 217.01M | 31.53M |
| Deferred Tax Liabilities | 4.94M | 3.52M | 2.27M | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 37.08M | 25.72M | 6.23M | 1.97M | 228.73M |
| Total Non-current Liabilities | 130.09M | 225.71M | 234.19M | 252.23M | 260.26M |
| Total Liabilities | 209.13M | 299.34M | 329.38M | 352.68M | 369.84M |
| Common Stock | 13K | 14K | 14K | 15K | 17K |
| Retained Earnings | (460.11M) | (554.77M) | (617.03M) | (671.86M) | (671.31M) |
| Accumulated OCI | (31K) | (23K) | (25K) | (25K) | (25K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 95.23M | 45.19M | (6.78M) | (29.62M) | 13.69M |
| Total Debt | 88.07M | 198.06M | 229.19M | 271.45M | 37.76M |
| Net Debt | 20.8M | 76.09M | 161.74M | 199.83M | (73.28M) |
Xeris Biopharma Holdings, Inc.
NASDAQ:XERS
Intrinsic Alpha fair value
Locked
Current Price
$16.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.